The European Commission (EC) has granted conditional marketing authorization for Calliditas Therapeutics’ Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.
Kinpeygo is an orphan medicinal product and the first and only approved treatment for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need, with more than 50% of patients potentially progressing to end-stage renal disease (ESRD). Kinpeygo will be marketed in the European Economic Area (EEA) exclusively by STADA Arzneimittel AG.
The conditional marketing authorization applies in all 27 European Union Member States as well as Iceland, Norway and Liechtenstein. Calliditas will transfer the Marketing Authorization for Kinpeygo to its commercial partner STADA, who plans to launch Kinpeygo in the EEA in the second half of 2022.
“We are excited to receive the formal approval of Kinpeygo in the EEA as the first and only EMA approved medication for this disease. We look forward to continuing to work with our European partner, Stada, as they prepare for commercialization,” said CEO Renée Aguiar-Lucander.
The Kinpeygo approval is based on the efficacy and safety data of Part A of the NeflgArd pivotal Phase 3 study, an ongoing, randomized, double-blind, placebo-controlled, multicentre study conducted to evaluate Kinpeygo 16 mg once daily oral dose vs placebo in adult patients with primary IgAN.
The effect of Kinpeygo, which was developed under the name Nefecon, was assessed in patients with biopsy-proven IgAN, eGFR ≥35 mL/min/1.73 m2, and proteinuria (defined as ≥1 g/day) who were on a stable dose of recommended or maximum tolerated RAS blockade. Patients taking 16mg of Kinpeygo once daily showed a statistically significant 31% reduction in proteinuria from baseline vs 5% in the placebo arm after 9 months of treatment.
After 9 months of treatment, Kinpeygo 16 mg once daily provided a statistically significant and clinically relevant 7% treatment benefit on eGFR compared to placebo (p=0.0014). This 3.87 mL/min/1.73 m2 treatment benefit at 9 months corresponded to a slight reduction from baseline of 0.17 mL/min/1.73 m2 in patients who received Kinpeygo 16 mg once daily and a deterioration from baseline of 4.04 mL/min/1.73 m2 in patients who received placebo.